Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
Trial details
- Registry ID
- NCT06526377
- Drugs studied
- vilamakitug
TrialRedline tracks 3 clinical trials sponsored by XBiotech, Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for EfficacyNCT06526377 | vilamakitug | Not yet recruiting | 2028-09Estimated |
| Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentNCT06590090 | Methotrexate (MTX), Natrunix 400 mg | Not yet recruiting | 2027-01-15Estimated |
| Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisNCT05363891 | Natrunix | Completed | 2024-10-31Actual |
Names as written in the registry records.
NCT06526377 · XBiotech, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Assessment of Spondyloarthritis International Society (ASAS) criteria will be used to determine proportion of subjects achieving 40% Improvement (ASAS40 response). After: Measure: Percentage of participants achieving ASAS40..
Before: 60 participants (planned). After: 150 participants (planned).
Before: 28 Feb 2027. After: Sep 2028.
NCT06526377 · XBiotech, Inc.
Before: 28 Feb 2025. After: 28 Feb 2027.
NCT06590090 · XBiotech, Inc.
Before: 15 Jan 2026. After: 15 Jan 2027.